{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T17:14:21Z","timestamp":1789751661562,"version":"4.0.1"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T00:00:00Z","timestamp":1684108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018353","name":"European Crohn's and Colitis Organisation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018353","id-type":"DOI","asserted-by":"publisher"}]},{"name":"European Society of Paediatric Gastroenterology"},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NAPP Pharmaceuticals"},{"DOI":"10.13039\/100010780","name":"Celltrion Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background and Aims<\/jats:title><jats:p>Vitamin D has a regulatory role in innate and adaptive immune processes. Previous studies have reported that low pretreatment vitamin D concentrations are associated with primary non-response (PNR) and non-remission to anti-TNF therapy. This study aimed to assess whether pretreatment 25-hydroxyvitamin D concentrations predicted PNR and non-remission to infliximab and adalimumab in patients with active luminal Crohn\u2019s disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>25-Hydroxyvitamin D concentrations were measured in stored baseline samples from 659 infliximab- and 448 adalimumab-treated patients in the Personalised Anti-TNF Therapy in Crohn\u2019s disease (PANTS) study. Cut-offs for vitamin D were deficiency &amp;lt;25 nmol\/L, insufficiency 25\u201350 nmol\/L, and adequacy\/sufficiency &amp;gt;50 nmol\/L.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>About 17.1% (189\/1107; 95% CI, 15.0\u201319.4) and 47.7% (528\/1107; 95% CI, 44.8\u201350.6) of patients had vitamin D deficiency and insufficiency, respectively. 22.2% (246\/1107) of patients were receiving vitamin D supplementation. Multivariable analysis confirmed that sampling during non-summer months, South Asian ethnicity, lower serum albumin concentrations, and non-treatment with vitamin D supplementation were independently associated with lower vitamin D concentrations. Pretreatment vitamin D status did not predict response or remission to anti-TNF therapy at week 14 (infliximab Ppnr = .89, adalimumab Ppnr = .18) or non-remission at week 54 (infliximab P = .13, adalimumab P = .58). Vitamin D deficiency was, however, associated with a longer time to immunogenicity in patients treated with infliximab, but not adalimumab.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Vitamin D deficiency is common in patients with active Crohn\u2019s disease. Unlike previous studies, pretreatment vitamin D concentration did not predict PNR to anti-TNF treatment at week 14 or nonremission at week 54.<\/jats:p><\/jats:sec>","DOI":"10.1093\/crocol\/otad026","type":"journal-article","created":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T15:45:36Z","timestamp":1684165536000},"source":"Crossref","is-referenced-by-count":13,"title":["Pretreatment Vitamin D Concentrations Do Not Predict Therapeutic Outcome to Anti-TNF Therapies in Biologic-Na\u00efve Patients With Active Luminal Crohn\u2019s Disease"],"prefix":"10.1093","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0207-6706","authenticated-orcid":false,"given":"Neil","family":"Chanchlani","sequence":"first","affiliation":[{"name":"Gastroenterology, Royal Devon University Healthcare NHS Foundation Trust , Exeter , UK"},{"name":"Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter , Exeter , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4201-4879","authenticated-orcid":false,"given":"Simeng","family":"Lin","sequence":"additional","affiliation":[{"name":"Gastroenterology, Royal Devon University Healthcare NHS Foundation Trust , Exeter , UK"},{"name":"Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter , Exeter , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1297-9773","authenticated-orcid":false,"given":"Rebecca","family":"Smith","sequence":"additional","affiliation":[{"name":"Gastroenterology, Royal Devon University Healthcare NHS Foundation Trust , Exeter , UK"},{"name":"Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter , Exeter , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6215-8044","authenticated-orcid":false,"given":"Christopher","family":"Roberts","sequence":"additional","affiliation":[{"name":"Gastroenterology, Royal Devon University Healthcare NHS Foundation Trust , Exeter , UK"},{"name":"Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter , Exeter , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Nice","sequence":"additional","affiliation":[{"name":"Biochemistry, Exeter Clinical Laboratory International, Royal Devon University Healthcare NHS Foundation Trust , Exeter , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3559-6660","authenticated-orcid":false,"given":"Timothy J","family":"McDonald","sequence":"additional","affiliation":[{"name":"Biochemistry, Exeter Clinical Laboratory International, Royal Devon University Healthcare NHS Foundation Trust , Exeter , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0349-278X","authenticated-orcid":false,"given":"Benjamin","family":"Hamilton","sequence":"additional","affiliation":[{"name":"Gastroenterology, Royal Devon University Healthcare NHS Foundation Trust , Exeter , UK"},{"name":"Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter , Exeter , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Bishara","sequence":"additional","affiliation":[{"name":"Gastroenterology, Royal Devon University Healthcare NHS Foundation Trust , Exeter , UK"},{"name":"Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter , Exeter , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0965-9587","authenticated-orcid":false,"given":"Claire","family":"Bewshea","sequence":"additional","affiliation":[{"name":"Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter , Exeter , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4368-1961","authenticated-orcid":false,"given":"Nicholas A","family":"Kennedy","sequence":"additional","affiliation":[{"name":"Gastroenterology, Royal Devon University Healthcare NHS Foundation Trust , Exeter , UK"},{"name":"Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter , Exeter , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3112-376X","authenticated-orcid":false,"given":"James R","family":"Goodhand","sequence":"additional","affiliation":[{"name":"Gastroenterology, Royal Devon University Healthcare NHS Foundation Trust , Exeter , UK"},{"name":"Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter , Exeter , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6058-5528","authenticated-orcid":false,"given":"Tariq","family":"Ahmad","sequence":"additional","affiliation":[{"name":"Gastroenterology, Royal Devon University Healthcare NHS Foundation Trust , Exeter , UK"},{"name":"Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter , Exeter , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,5,15]]},"reference":[{"issue":"11","key":"2023053115095562500_CIT0001","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1177\/1535370214523890","article-title":"Vitamin D, immune regulation, the microbiota, and inflammatory bowel disease","volume":"239","author":"Cantorna","year":"2014","journal-title":"Exp Biol Med (Maywood)."},{"issue":"2","key":"2023053115095562500_CIT0002","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.crohns.2011.08.002","article-title":"Vitamin D deficiency in Crohn\u2019s disease: prevalence, risk factors and supplement use in an outpatient setting","volume":"6","author":"Nic Suibhne","year":"2012","journal-title":"J Crohns Colitis"},{"issue":"9","key":"2023053115095562500_CIT0003","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1111\/j.1365-2036.2005.02446.x","article-title":"Seasonality of vitamin D status and bone turnover in patients with Crohn\u2019s disease","volume":"21","author":"McCarthy","year":"2005","journal-title":"Aliment Pharmacol Ther."},{"issue":"5","key":"2023053115095562500_CIT0004","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/ajg.2016.53","article-title":"Association of vitamin D level with clinical status in inflammatory bowel disease: a 5-year longitudinal study","volume":"111","author":"Kabbani","year":"2016","journal-title":"Am J Gastroenterol."},{"issue":"3","key":"2023053115095562500_CIT0005","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1053\/j.gastro.2011.11.040","article-title":"Higher predicted vitamin D status is associated with reduced risk of Crohn\u2019s disease","volume":"142","author":"Ananthakrishnan","year":"2012","journal-title":"Gastroenterology."},{"issue":"8","key":"2023053115095562500_CIT0006","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1016\/j.cgh.2019.09.034","article-title":"Levels of vitamin D are low after Crohn\u2019s disease is established but not before","volume":"18","author":"Limketkai","year":"2020","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"9","key":"2023053115095562500_CIT0007","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1210\/jc.2018-00250","article-title":"Vitamin D and inflammatory bowel disease: Mendelian randomization analyses in the Copenhagen studies and UK Biobank","volume":"103","author":"Lund-Nielsen","year":"2018","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"2023053115095562500_CIT0008","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1093\/ibd\/izx050","article-title":"Prediagnostic serum vitamin D levels and the risk of Crohn\u2019s disease and ulcerative colitis in European populations: a nested case\u2013control study","volume":"24","author":"Opstelten","year":"2018","journal-title":"Inflamm Bowel Dis."},{"issue":"10","key":"2023053115095562500_CIT0009","doi-asserted-by":"crossref","first-page":"e407","DOI":"10.1016\/j.crohns.2013.01.012","article-title":"Active Crohn\u2019s disease is associated with low vitamin D levels","volume":"7","author":"J\u00f8rgensen","year":"2013","journal-title":"J Crohns Colitis"},{"issue":"12","key":"2023053115095562500_CIT0010","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1097\/01.MIB.0000436957.77533.b2","article-title":"Association of circulating vitamin D concentrations with intestinal but not systemic inflammation in inflammatory bowel disease","volume":"19","author":"Garg","year":"2013","journal-title":"Inflamm Bowel Dis."},{"issue":"7","key":"2023053115095562500_CIT0011","first-page":"889","article-title":"Determinants of vitamin D status in adult Crohn\u2019s disease patients, with particular emphasis on supplemental vitamin D use","volume":"60","author":"Gilman","year":"2006","journal-title":"Eur J Clin Nutr 2006 607."},{"key":"2023053115095562500_CIT0012","first-page":"100","article-title":"Vitamin D deficiency in inflammatory bowel disease: prevalence and predictors in a Norwegian outpatient population","volume-title":"Scand J Gastroenterol","author":"Frigstad","year":"2016"},{"key":"2023053115095562500_CIT0013","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","article-title":"British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults","volume":"68","author":"Lamb","year":"2019","journal-title":"Gut."},{"issue":"2","key":"2023053115095562500_CIT0014","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S2468-1253(21)00223-5","article-title":"Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives","volume":"7","author":"Papamichael","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"2023053115095562500_CIT0015","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S2468-1253(19)30012-3","article-title":"Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn\u2019s disease: a prospective, multicentre, cohort study","volume":"4","author":"Kennedy","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"2023053115095562500_CIT0016","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/apt.17089","article-title":"Understanding anti-TNF treatment failure: does serum triiodothyronine-to-thyroxine (T3\/T4) ratio predict therapeutic outcome to anti-TNF therapies in biologic-na\u00efve patients with active luminal Crohn\u2019s disease?","volume":"56","author":"Lin","year":"2022","journal-title":"Aliment Pharmacol Ther."},{"issue":"1","key":"2023053115095562500_CIT0017","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1053\/j.gastro.2019.09.041","article-title":"HLA-DQA1*05 carriage associated with development of anti-drug antibodies to infliximab and adalimumab in patients with Crohn\u2019s disease","volume":"158","author":"Sazonovs","year":"2020","journal-title":"Gastroenterology."},{"issue":"3","key":"2023053115095562500_CIT0018","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/apt.15563","article-title":"HLADQA1*05 genotype predicts anti-drug antibody formation and loss of response during infliximab therapy for inflammatory bowel disease","volume":"51","author":"Wilson","year":"2020","journal-title":"Aliment Pharmacol Ther."},{"issue":"5","key":"2023053115095562500_CIT0019","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/apt.13936","article-title":"Higher 25-hydroxyvitamin D levels are associated with greater odds of remission with anti-tumour necrosis factor-\u03b1 medications among patients with inflammatory bowel diseases","volume":"45","author":"Winter","year":"2017","journal-title":"Aliment Pharmacol Ther."},{"issue":"3","key":"2023053115095562500_CIT0020","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1177\/0148607113504002","article-title":"Pretreatment 25-hydroxyvitamin D levels and durability of anti-tumor necrosis factor-\u03b1 therapy in inflammatory bowel diseases","volume":"38","author":"Zator","year":"2014","journal-title":"JPEN J Parenter Enteral Nutr."},{"key":"2023053115095562500_CIT0021","doi-asserted-by":"crossref","first-page":"789","DOI":"10.3389\/fnut.2021.739285","article-title":"Influence of Vitamin D3 supplementation on infliximab effectiveness in Chinese patients with Crohn\u2019s disease: a retrospective cohort study","volume":"8","author":"Xia","year":"2021","journal-title":"Front Nutr"},{"key":"2023053115095562500_CIT0022","author":"Roche Diagnostics.","year":"2018"},{"issue":"2","key":"2023053115095562500_CIT0023","doi-asserted-by":"crossref","first-page":"e23037","DOI":"10.1002\/jcla.23037","article-title":"The pre-analytical stability of 25-hydroxyvitamin D: Storage and mixing effects","volume":"34","author":"Borai","year":"2020","journal-title":"J Clin Lab Anal."},{"issue":"1","key":"2023053115095562500_CIT0024","first-page":"0","article-title":"Pre-analytical stability of 25 hydroxy vitamin D in human serum","volume":"1","author":"Bozkurt","year":"2018","journal-title":"Int J Med Biochem."},{"issue":"1","key":"2023053115095562500_CIT0025","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/apt.16135","article-title":"Validating the positivity thresholds of drug-tolerant anti-infliximab and anti-adalimumab antibody assays","volume":"53","author":"Nice","year":"2021","journal-title":"Aliment Pharmacol Ther."},{"issue":"10","key":"2023053115095562500_CIT0026","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1111\/apt.13997","article-title":"Editorial: clinical benefits of vitamin D therapy in inflammatory bowel disease","volume":"45","author":"Hawthorne","year":"2017","journal-title":"Aliment Pharmacol Ther."},{"issue":"5","key":"2023053115095562500_CIT0027","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1097\/MIB.0000000000000697","article-title":"The relevance of vitamin D and antinuclear antibodies in patients with inflammatory bowel disease under anti-TNF treatment: a prospective study","volume":"22","author":"Santos-Antunes","year":"2016","journal-title":"Inflamm Bowel Dis."},{"key":"2023053115095562500_CIT0028","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3389\/fphys.2014.00151","article-title":"Impact of vitamin D on immune function: lessons learned from genome-wide analysis","volume":"5","author":"Chun","year":"2014","journal-title":"Front Physiol."}],"container-title":["Crohn's &amp; Colitis 360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/advance-article-pdf\/doi\/10.1093\/crocol\/otad026\/50329659\/otad026.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article-pdf\/5\/3\/otad026\/50495402\/otad026.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article-pdf\/5\/3\/otad026\/50495402\/otad026.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T23:46:37Z","timestamp":1702424797000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article\/doi\/10.1093\/crocol\/otad026\/7162673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,15]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/crocol\/otad026","relation":{},"ISSN":["2631-827X"],"issn-type":[{"value":"2631-827X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,7,1]]},"published":{"date-parts":[[2023,5,15]]},"article-number":"otad026"}}